NEW YORK, May 30 – Incyte Genomics and Iconix Pharmaceuticals announced on Wednesday a collaboration to develop and commercialize the next-generation of Iconix’s ChemExpress chemogenomic platform.

Incyte will exclusively market and sell ChemExpress, according to the companies. Iconix will integrate Incyte’s LifeExpress Lead databases into ChemExpress under an exclusive license from Incyte, the companies announced. Under the terms of the agreement, Incyte will make an equity investment in Iconix.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.